Prophylactic or therapeutic drug for neurodegenerative diseases
AssigneeMedilabo Rfp, Inc.
InventorsTakami Tomiyama, Tomohiro Umeda, Toru Kumagai
Life of this patent
Estimating the term…
Abstract
A technique of administering rifampicin over an extended period of time, with reduced side effects. A medicine that is for nasal administration and is used to prevent or treat neurodegenerative diseases, contains a rifampicin selected from the group consisting of rifampicin, derivatives thereof, and salts thereof, and a resveratrol selected from resveratrol and derivatives thereof, has reduced side effects, and can be administered over an extended period of time.
Claims2
A method for treating Alzheimer's disease in a patient comprising administering to the patient a pharmacological active component consisting of a combination of:
- a rifampicin compound selected from the group consisting of rifampicin, a derivative of rifampicin, a salt of rifampicin and a salt of a derivative of rifampicin, and a resveratrol compound selected from the group consisting of resveratrol and a derivative of resveratrol;
- wherein the derivative of rifampicin is selected form the group consisting of 3-formyl-rifamycin SV, rifamycin S, rifamycin B, rifamycin SV and 25-desacetyl-rifampicin, and the derivative of resveratrol is a resveratrol having a derivative group selected from the group consisting of N-phenylacetyl group, 4,4′-dimethoxytrityl (DMT) group, protein group, peptide group, sugar group, lipid group, nucleic acid group, polystyrene group, polyethylene group, polyvinyl polyester group, and ester group.
Dependencies are inferred from the claim text.